Pharmalot

By  Ed Silverman

Taking stock of the drug industry, from the lab to the medicine chest. Sign up for the newsletter here.

Gilead
Pharmalot

As Gilead plans a C-suite succession, the rash of top-level departures continues

By Ed Silverman

Pharmalot

Pharmalittle: More turnover at Gilead Sciences; EMA scales back its transparency policy

By Ed Silverman

Pharmalot

CVS sets a cost-effectiveness threshold for health plan coverage of most new drugs

By Ed Silverman

CVS/Aetna
Pharmalot

Ohio Medicaid cancels contracts with two big PBMs over ‘spread’ pricing

By Ed Silverman

Charlie Baker
Pharmalot

To lower state drug costs, the National Governors Association is promoting several ideas

By Ed Silverman

Pharmalot

Pharmalittle: U.K. watchdog calls Biogen rare disease drug too pricey; Novartis hires a new ethics officer

By Ed Silverman

Pharmalot

Gilead patent for its hepatitis C drug is invalidated by Chinese authorities

By Ed Silverman

Pharmalot

Pharmalittle: Icahn dealt setbacks in bid to derail Cigna deal for Express Scripts; Pfizer suit against J&J proceeds

By Ed Silverman

FDA; Drug Administration campus
Pharmalot

FDA found problems at Chinese ingredients maker nearly two years before valsartan recalls

By Ed Silverman

Hires
Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: FDA approved record number of generics in July; feds join suits against Suboxone maker

By Ed Silverman

Vertex Pharmaceuticals Inc. building
Pharmalot

In clash over pricing, Vertex won’t give U.K. data needed to review a new cystic fibrosis drug

By Ed Silverman

India Tuberculosis Villages
Pharmalot

Lawmakers urge Trump to ensure access to TB drugs as UN meeting nears

By Ed Silverman

Pharmalot

Pharmalittle: Mylan is evaluating its options; GW will charge $32,500 for its cannabinoid for epilepsy

By Ed Silverman

Hepatitis C
Pharmalot

Louisiana explores a ‘Netflix’ subscription model for buying hepatitis C drugs

By Ed Silverman

John Kapoor
Pharmalot

Insys agrees to pay $150 million to settle federal probe into opioid marketing

By Ed Silverman

Injectable drugs
Pharmalot

Trump plan to give private Medicare leverage over drug costs would boost PBMs and biosimilars

By Ed Silverman

Pharmalot

AstraZeneca to pay $110 million to Texas for defrauding Medicaid and illegally marketing drugs

By Ed Silverman

Pharmalot

Pharmalittle: Trump plans drug price announcement next week; CMS targets Medicare Part B for negotiation

By Ed Silverman

Pharmacy Benefit Managers
Pharmalot

Express Scripts to drop dozens more drugs from its formulary next year

By Ed Silverman

Pharmalot

Would reforming the U.S. patent system help to lower drug prices?

By Ed Silverman

Pharmalot

Pharmalittle: Icahn calls Cigna deal for Express Scripts ‘ridiculous’; U.K. may place price controls on biosimilars

By Ed Silverman

Pill map - United States
Pharmalot

When more is less: Americans spent lots more on fewer pills

By Ed Silverman

Pharmalot

Pharmalittle: Celgene raised prices in the U.S, but dropped them in Russia; Pain CEO criticizes ‘bizarre’ FDA rejection

By Ed Silverman

CAR-T Cell Therapies
Biotech

Regeneron and Bluebird Bio strike a deal to discover and develop cancer treatments

By Ed Silverman

Gavel and Stethoscope
Pharmalot

A New Jersey court gives pharma a boost in lawsuits filed by consumers

By Ed Silverman

Painkillers
Pharmalot

A congressional committee steps up the pressure on opioid makers

By Ed Silverman

Hires
Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: A biotech incubator bought a brokerage to tout its firms; FDA failed to thwart risky fentanyl prescribing

By Ed Silverman

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy